Home [sandbox] K4D COVID-19 Resource Hub Zotero / K4D COVID-19 Health Evidence Summaries Group / Top-Level Items Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial